Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Curaxys, The New Spanish Biopharmaceutical Company Pioneer On Biopharmaceuticals BiosimilarsCuraxys is the new company specialized in the production of biosimilars medicines. It is an independent private company, located on the technological park of Cadiz (Spain). The new venture is focuses in the development of new technological platform f
By: APSA Press release. Spain Technologies: It is remarkable to inform that in the last 20 years have demonstrated that the baculoviruses maintains a reputation for producing high yields of recombinant proteins in insect cells. Despite the difficulties of working with a virus in eukaryotic cells, the fact that posttranslational modifications such as glycosylation, fatty acid acylacion , disulfide bond formation, and phosphorylation are carried out very similar to the same process in mammalian cells, demonstrating the value of bacuviruses as expression vectors. We offer a complete range of biopharmaceuticals biosimilars with structure, recombinant protein and monoclonal antibody. The products are focused to improve the quality of life of patient with new concept of product at reasonable cost in the field of the immunology, cancer treatment, multiple sclerosis, and virology. The productscurrently in pharmaceutical developement are: Recombinants proteins 1. Insulin 2. Growth Hormone 3. Erythropoietin 4. Granulocyte Colony Stimulating Factor ( GCSF) Monoclonal Antibodies 1. Rituximab 2. Trastuzumab The founder and CEO and of the company is Dr. Manuel Esteban, PhD, MSc, MBA,. He has over three decades of experience in pharmaceutical and biopharmaceutical research conducted at leading pharmaceutical companies such as Juste SAQF, Sanofi-Aventis, DSM Pharmaceuticals and Antibioticos (Montedison) Dr. Esteban has held a variety of research management roles in projects related to cell and microorganism culture, technological development, as well as chemical, biochemical and enzymatic technologies. He is also a proven business manager with the ability to bring in new clients, to create new companies and to develop business opportunities. # # # Curaxys is specialized in creating original technologies to develop new biological process useful for the production of therapeutical biological compounds: BIOSIMILARS. The biological process used are the result of an exclusive technological partnership with universities, research institutions and biotechnological ocmpnaies and CMO. The technologies applied are based on microbial fermentation, mammalian cell culture, insect cell culture using a Baculovirus Expression Vector System (BEVS) Protocol for the production of recombinant proteins and transgenic plant. The technologies allows to us to produce therapeutical proteins of great interest as biosimilars End
Account Email Address Disclaimer Report Abuse
|
|